Exelixis Q2 revenue missed estimates, but strong Cabometyx sales lifted earnings. STELLAR trial delays and strategy shifts shaped the update.
Latest Ratings for EXEL
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | HC Wainwright & Co. | Maintains | Buy | |
| Nov 2021 | RBC Capital | Maintains | Outperform | |
| Nov 2021 | HC Wainwright & Co. | Maintains | Buy |
